The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2
Advanced Science · 2025
DOI: 10.1002/advs.202500912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lingkai Gu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Maternal and Infant Health, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China. Hauptthemen laut MEDLINE: Extracellular Vesicles, HMGA2 Protein, Ovarian Neoplasms, Fibroblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ovarian cancer is an aggressive gynecological tumor usually diagnosed with widespread metastases. Extracellular vesicles (EVs), though recognized as important mediators of tumor metastasis, have received limited attention into their specific functions via the mRNA profiling. Here it is reported elevated expression and selective enrichment of INAVA mRNA in both plasma‐ and tissue‐derived EVs from ovarian cancer patients, which is positively correlated with distant metastasis and poor prognosis. Functionally, INAVA mRNA, upon uptake and translation, activates normal ovarian fibroblasts (NOFs) and drives extensive peritoneum metastasis in the orthotopic xenograft mouse model. Mechanistically, INAVA competitively binds with high mobility group protein A2 (HMGA2) and consequently inhibit its interaction with vaccinia‐related kinase 1 (VRK1), leading to reduced HMGA2 phosphorylation on Ser105. Interestingly, this inhibitory phosphorylation stabilizes HMGA2 via blocking tripartite motif‐containing 21 (TRIM21) ‐mediated K48‐linked ubiquitylation, and ultimately enhances the transcription of STAT3 to activate NOFs. Lastly, a cell‐permeable peptide that disrupts the INAVA–HMGA2 interaction leads to attenuated NOF activation and provides a promising strategy for ovarian cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Key Laboratory of Maternal and Infant Health, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
- Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
- Department of Gynecologic Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
- Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, 310029, China.
- Cancer Center, Zhejiang University, Hangzhou, 310058, China.
- Zhejiang Provincial Clinical Research Center for Cancer, Hangzhou, 310009, China.
ORCID-Profile: Weiguo Lu
Förderung
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Gu, L., Shen, Z., Shen, S., Wang, C., Liu, Y., Wei, X., Zheng, M., Gu, J., Chen, X., Sun, Y., Xu, J., Lu, Y., & Lu, W. (2025). The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2. Advanced Science. https://doi.org/10.1002/advs.202500912
Vancouver
Gu L, Shen Z, Shen S, Wang C, Liu Y, Wei X, et al. The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2. Advanced Science. 2025. doi:10.1002/advs.202500912
BibTeX
@article{Gu2025,
author = {Gu, Lingkai and Shen, Zhangjin and Shen, Shizhen and Wang, Conghui and Liu, Yuwan and Wei, Xinyi and Zheng, Mengxia and Gu, Jiaxin and Chen, Xiaojing and Sun, Yi and Xu, Junfen and Lu, Yan and Lu, Weiguo},
title = {The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202500912}
}
EUVIMED